광물 자원에서 유래된 원료 의약품 및 첨가제의 사례 연구 = Case Study of Pharmaceutical Ingredients Derived from Clay Minerals

국문 초록 (Abstract)

약학 분야에서 점토광물은 점토광물 자체의 약리작용을 확인하고 원료의약품으로 활용하거나 희석제, 유화제, 점증제, 활택제 등 의약품 제형의 완성도를 높이는 첨가제로서 사용되고 있다. 벤토나이트(Bentonite), 카올린(Kaolin), 규산알루민산마그네슘(Magnesium aluminum silicate), 탤크(Talc) 등은 원료의약품 혹은 첨가제로서 활용 가능한 대표적인 점토 광물로 국내외 의약품 공정서에 수재되어 있고, 약학적 활용시 의약품등급으로 규제되고 있다. 본 논문에서는 공정서에 수재된 점토 광물을 중심으로 공정서의 규격을 확인하고, 점토광물의 특성 및 원료의약품 혹은 의약품 첨가제로서의 점토 광물에 대한 활용 사례를 소개하고자 한다. 결론적으로 점토광물을 제약산업에 활용하는 것은 점토광물의 고부가가치화를 위한 한 가지 방법이 될 수 있으며, 자원의 개발 및 활용이라는 측면에서 매우 유용할 것이라 사료된다.

다국어 초록 (Multilingual Abstract)

Clay minerals have been used in pharmaceutical industries as active ingredients and excipients without pharmacological activity such as diluents, emulsifying agents, viscosity-increasing agents, and lubricants. For example, bentonite, kaolin, magnesium aluminum silicate, and talc are generally and extensively used pharmaceutical ingredients, which are restrictedly regulated by Pharmacopoeias. We discuss the physicochemical and biopharmaceutical properties of clay minerals. In addition, we introduce the cases of pharmaceutical applications of clay minerals. From this review, pharmaceutical applications of clay minerals can be one of strategies for the development of high value-added products from clay minerals.

참고문헌 (Reference)

1 Masanaba, S, "Toxicological evaluation of clay minerals and derived nanocomposites: a review" 138 : 233-254, 2015

2 Hong, Y, "Topical ketanserin attenuates hyperalgesia and inflammation in arthritis in rats" 124 : 27-33, 2006

3 Rodrigues, L. A, "The systems containing clays and clay minerals from modified drug release: a review" 103 : 642-651, 2013

4 Bailey, SW, "Summary of recommendations of AIPEA" 65 : 1-7, 1980

5 Moyo, F, "Sorption of hydrophobic organic compounds on natural sorbents and organoclays from aqueous and nonaqueous solutions: a mini-review" 11 : 5020-5048, 2014

6 Hopkins, J. G, "Some Newer Bases for Use in Cutaneous Therapy" 7 : 171-174, 1946

7 Hajizadeh, SHajizadeh S, "Responsiveness of vascular alpha1-adrenoceptors of diabetic rat knee joint to phenylephrine in acute inflammation" 16 : 301-309, 2005

8 Dogan, M, "Quantitative mineralogical properties (morphology-chemistry-structure) of pharmaceutical grade kaolinites and recommendations to regulatory agencies" 18 : 143-151, 2012

9 Viseras, C, "Pharmaceutical grade phyllosilicate dispersions: the influence of shear history on floc structure" 182 : 7-20, 1999

10 Goel, H, "Orally disintegrating systems: innovations in formulation and technology" 2 : 258-274, 2008

11 Rieder, M, "Nomenclature of micas" 46 : 586-595,

12 Calabrese, I, "Montmorillonite nanodevices for the colon metronidazole delivery" 457 : 224-236, 2013

13 Dvinskikh, S. V, "MRI profiles over very wide concentration ranges: application to swelling of a bentonite clay" 198 : 146-150, 2009

14 Campbell, K.T, "Ibuprofen-loaded poly(epsilon-caprolactone) layered silicate nanocomposites prepared by hot melt extrusion" 21 : 2307-2316, 2010

15 Otto, C. C, "Exchangeable ions are responsible for the in vitro antibacterial properties of natural clay mixtures" 17 : e64068-, 2013

16 Valenti, D. M, "Effect of topical clay application on the synthesis of collagen in skin: an experimental study" 37 : 164-168, 2012

17 el-Sayed, A.M, "Dissociation constant of chlordiazepoxide in montmorillonite suspension and its pharmaceutical application for a controlled-release dosage form" 63 : 257-266, 1993

18 Elmore, A.R, "Cosmetic Ingredient Review Expert Panel. Final report on the safety assessment of aluminum silicate, calcium silicate, magnesium aluminum silicate, magnesium silicate, magnesium trisilicate, sodium magnesium silicate, zirconium silicate, attapulgite, bentonite, Fuller's earth, hectorite, kaolin, lithium magnesium silicate, lithium magnesium sodium silicate, montmorillonite, pyrophyllite, and zeolite" 22 : 37-102, 2003

19 Al-khattawi, A, "Compressed orally disintegrating tablets: excipients evolution and formulation strategies" 10 : 651-663, 2013

20 Carretero, M.I, "Clay and non-clay minerals in the pharmaceutical industry: Part I. Excipients and medical applications" 46 : 73-80, 2009

21 Carretero, M.I, "Clay and non-clay minerals in the pharmaceutical and cosmetic industries Part II. Active ingredients" 47 : 171-181, 2010

22 Viseras, C, "Characteristics of pharmaceutical grade phyllosilicate powders" 5 : 47-52, 2000

23 Oh, Y. J, "Aripiprazole-montmorillonite: a new organic-inorganic nanohybrid material for biomedical applications" 19 : 4869-4875, 2013

24 Paineau, E, "Aqueous suspensions of natural swelling clay minerals. 1. Structure and electrostatic interactions" 27 : 5562-5573, 2011

25 Loyd, V, "Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems" Lippincott Williams & Wilkins 107-188, 2011